AZN241122C67000
- 0.01
- 0.000.00%
AstraZeneca Newsroom
AstraZeneca's Strategic Focus and Clinical Trial Success Bolster Buy Rating
Failure of AstraZeneca's AZD4041 a Blow for Non-opioid OUD Treatments
Amgen (AMGN.US) released mid-term data on the weight loss therapy MariTide, showing weight loss effects comparable to Novo Nordisk.
Amgen announced on Tuesday that its experimental weight loss therapy MariTide achieved significant results in Phase 2 trials.
Astrazeneca (AZN.US) combination therapy Truqap phase 3 trial results are positive.
Astrazeneca (AZN.US) announced today the positive results of the CAPItello-281 Phase 3 clinical trial.
Astrazeneca's Capivasertib for prostate cancer has successfully completed Phase III trials, and the outlook for Kairui Pharmaceutical-B (2105.HK) AKT inhibitors is bullish.
On November 25th, AstraZeneca announced the success of its AKT inhibitor Capivasertib in the phase III CAPItello-281 study for the treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). Following the approval and launch of Capivasertib for breast cancer indications, this study further confirmed the clinical value of AKT inhibitors. AKT inhibitors, as drugs that have shown potential in multiple cancers such as breast cancer, prostate cancer, and ovarian cancer, have a very broad market outlook. In recent years, an increasing number of pharmaceutical companies have begun to pay attention to AKT inhibitors.
AstraZeneca Reports Positive Phase 3 Results for Truqap in Prostate Cancer
AstraZeneca (AZN) Receives a Buy From Goldman Sachs
TRUQAP (Capivasertib) Combination in PTEN-deficient Metastatic Hormone-sensitive Prostate Cancer Demonstrated Statistically Significant and Clinically Meaningful Improvement in Radiographic Progression-free Survival in CAPItello-281 Phase III Trial
AstraZeneca's Truqap Combo Demonstrated Statistically Significant Improvement
GCAR and AstraZeneca Execute Agreement to Evaluate AZD1390 for Glioblastoma
AstraZeneca's Prostate Cancer Treatment Trial Shows Clinically Meaningful Improvement
AstraZeneca (AZN): A Top Pick for Hedge Funds Due to Innovation and Rising Demand
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
Trump Nominates Marty Makary For FDA Commissioner
Top Gap Ups and Downs on Friday: AZN, BABA, PDD and More
European Equities Traded in the US as American Depositary Rise in Friday Trading, Up Over 1% for Week
Astrazeneca (AZN.US) and Amgen (AMGN.US) have reported the launch of a subcutaneous injection of TSLP monoclonal antibody in China.
CDE's official website shows that Astrazeneca (AZN.US) and Amgen (AMGN.US) have jointly submitted the application for the listing of TSLP monoclonal antibody Tezepelumab injection.
J.P. Morgan Remains a Buy on AstraZeneca (AZN)
AstraZeneca (AZN) Receives a Buy From Barclays
Amneal Gets FDA Approval for Generic Byetta, Resubmits DHE NDA